| Microfluidic manufacturing of phospholipid nanoparticles: Stability, encapsulation efficacy, and drug release MGS Correia, ML Briuglia, F Niosi, DA Lamprou International journal of pharmaceutics 516 (1-2), 91-99, 2017 | 118 | 2017 |
| Biopharmaceutical considerations in paediatrics with a view to the evaluation of orally administered drug products–a PEARRL review M Guimarães, M Statelova, R Holm, C Reppas, M Symilllides, M Vertzoni, ... Journal of Pharmacy and Pharmacology 71 (4), 603-642, 2019 | 37 | 2019 |
| Performance Evaluation of Montelukast Pediatric Formulations: Part II—a PBPK Modelling Approach M Guimarães, M Vertzoni, N Fotaki The AAPS Journal 24 (1), 27, 2022 | 5 | 2022 |
| Investigating the critical variables of azithromycin oral absorption using in vitro tests and PBPK modeling M Guimarães, P Somville, M Vertzoni, N Fotaki Journal of Pharmaceutical Sciences 110 (12), 3874-3888, 2021 | 5 | 2021 |
| Performance Evaluation of Montelukast Pediatric Formulations: Part I—Age-Related In Vitro Conditions M Guimarães, P Somville, M Vertzoni, N Fotaki The AAPS Journal 24 (1), 26, 2022 | 3 | 2022 |
| Understanding the Impact of Age-Related Changes in Pediatric GI Solubility by Multivariate Data Analysis M Guimarães, A Maharaj, A Edginton, M Vertzoni, N Fotaki Pharmaceutics 14 (2), 356, 2022 | 1 | 2022 |
| Evaluating pediatric and adult simulated fluids solubility: Abraham solvation parameters and multivariate analysis M Guimarães, M Kuentz, M Vertzoni, N Fotaki Pharmaceutical Research 38, 1889-1896, 2021 | 1 | 2021 |
| Developing in vitro and in silico approaches to predict clinical outcomes: focus on paediatrics M Guimarães | | 2021 |
| Applying PBPK Modeling to Predict Drug Exposure in Special Populations M Guimarães, M Murshed, J Pineiro-Llanes, R Cristofoletti, N Fotaki The Art and Science of Physiologically-Based Pharmacokinetics Modeling, 162-179, 0 | | |
Nikoletta FotakiProfessor of Biopharmaceutics, University of Bath, UK在 bath.ac.uk 的电子邮件经过验证
